Last reviewed · How we verify

AL001 — Competitive Intelligence Brief

AL001 (AL001) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TREM2 agonist monoclonal antibody. Area: Neurology.

phase 3 TREM2 agonist monoclonal antibody TREM2 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AL001 (AL001) — Alector Inc.. AL001 is a monoclonal antibody that activates TREM2 signaling on microglia to promote neuroinflammatory resolution and clearance of pathogenic proteins in neurodegenerative disease.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AL001 TARGET AL001 Alector Inc. phase 3 TREM2 agonist monoclonal antibody TREM2
AL003 AL003 Alector Inc. marketed TREM2 activator monoclonal antibody TREM2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TREM2 agonist monoclonal antibody class)

  1. Alector Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AL001 — Competitive Intelligence Brief. https://druglandscape.com/ci/al001. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: